Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly has agreed to acquire privately held Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and potential milestone payments based on clinical and regulatory achievements. Ajax's lead drug, AJ1-11095, is in early-stage trials for myelofibrosis.
Tickers: $LLY
Topics: acquisition Ajax Therapeutics blood cancer treatment Eli Lilly pharmaceuticals